A chatbot therapist to help combat depression quicker has been launched.
The bot has been launched as recent figures show that NHS patients seeking help with their mental health are waiting more than eight weeks to see a doctor after their first appointment.
The chatbot therapist was developed by medical device company Flow, which in June launched a brain stimulation headset treatment for depression, the first and only medically approved at-home treatment of its kind in the UK and EU.
The chatbot therapist, called Flow, engages users with daily chat conversations and offers self-help techniques, mood tracking, curated videos, meditation and mental exercises. It helps users to learn why sleep, exercise, nutrition and meditation are the main pillars in recovering from depression, and gathers mood data to offer a personalised response modelled on behavioural therapy.
One Flow user stated: “I feel like I have a buddy who’s just chatting with me, no judgement, and forcing me to pace myself.”
Available for free
Available to download free on iOS, the chatbot therapist is based on the latest psychology and neuroscience research, and was developed by clinical psychologists and machine learning experts. An Android version will be available in October 2019.
Nearly one in four adults in the UK are affected by a mental illness and suicide is the most common cause of death for men aged 20-49 years in England and Wales. The economic costs of mental illness in England is estimated at £105.2bn (~€118.72bn) annually and one in three work sickness notes handed out by GPs are for mental health reasons, including depression.
Daniel Mansson, Clinical Psychologist, CEO and Co-Founder of Flow, said: “Accessibility and early intervention in depression is crucial. The ‘always-on’ source of therapy provided by Flow ensures people get the help they need as quickly as possible.
“Flow can provide anonymity without the fear of being judged by others. This is great as some people feel anxious when it comes to talking about their depression to another human.”
Flow can be used in conjunction with the Flow brain stimulation headset to maximise the chance of recovery. Randomised controlled trials published in the New England Journal of Medicine and the British Journal of Psychiatry show that brain stimulation, of the type used in the Flow headset, had a similar impact to antidepressants but with fewer and less-severe side effects.
Flow joins a growing number of mental health chatbots, including Woebot and Wysa, which are playing an increasing role in the mental health landscape. Whilst Woebot and Wysa use a cognitive behavioural approach to change the way people think, Flow has one goal: to reduce clinical depression based on well-grounded science.
Flow is starting talks with the NHS to have its brain stimulation headset available on prescription. The company recently announced an investment of £1.2m (~€1.35m) by Khosla Ventures to roll out its offering across Europe, introduce the Flow headset to healthcare clinics in the UK, and fund clinical studies.